Dong Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dong Gao has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chih-Chang Wei
Shenzhen Hornetcorn Biotechnology Co., Ltd., Shenzhen, 518045, China
1 shared publication - Jian Chen
Department of Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. China
1 shared publication - Li Wang
Affiliated Mental Health Centre & Hangzhou Seventh People’s Hospital, Zhejiang University School of Medicine , Hangzhou
1 shared publication - Min Liu
Department of Orthopedics, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China
1 shared publication Peiwen Lian
Department of Laboratory and Oncology, Yantai Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China
1 shared publication- Peiying Zhang
Department of Cardiology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China
1 shared publication
Latest Publications
- Open Access
- 1 November 2019
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 34 (11) , e201901104
Biochanin A attenuates myocardial ischemia/reperfusion injury through the TLR4/NF-κB/NLRP3 signaling pathway
Myocardial ischemia/reperfusion (Ml/R) injury is a leading cause of damage in cardiac tissues, with high rates of mortality and disability. Biochanin A (BCA) is a main constituent of Trifolium pratense L. This study was intended to explore the effect of BCA on Ml/R injury and explore the potential mechanism. In vivo MI/R injury was established by transient coronary ligation in Sprague-Dawley rats. Triphenyltetrazolium chloride staining (TTC) was used to measure myocardial infarct size. ELISA assay was employed to evaluate the levels of myocardial enzyme and inflammatory cytokines. Western blot assay was conducted to detect related protein levels in myocardial tissues. BCA significantly ameliorated myocardial infarction area, reduced the release of myocardial enzyme levels including aspartate transaminase (AST), creatine kinase (CK-MB) and lactic dehydrogenase (LDH). It also decreased the production of inflammatory cytokines (IL-1β, IL-18, IL-6 and TNF-α) in serum of Ml/R rats. Further mechanism studies demonstrated that BCA inhibited inflammatory reaction through blocking TLR4/NF-kB/NLRP3 signaling pathway. The present study is the first evidence demonstrating that BCA attenuated Ml/R injury through suppressing TLR4/NF-kB/NLRP3 signaling pathway-mediated anti-inflammation pathway.
- 1 November 2019
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 34 (11) , e201901104
Open AccessBiochanin A attenuates myocardial ischemia/reperfusion injury through the TLR4/NF-κB/NLRP3 signaling pathway
Myocardial ischemia/reperfusion (Ml/R) injury is a leading cause of damage in cardiac tissues, with high rates of mortality and disability. Biochanin A (BCA) is a main constituent of Trifolium pratense L. This study was intended to explore the effect of BCA on Ml/R injury and explore the potential mechanism. In vivo MI/R injury was established by transient coronary ligation in Sprague-Dawley rats. Triphenyltetrazolium chloride staining (TTC) was used to measure myocardial infarct size. ELISA assay was employed to evaluate the levels of myocardial enzyme and inflammatory cytokines. Western blot assay was conducted to detect related protein levels in myocardial tissues. BCA significantly ameliorated myocardial infarction area, reduced the release of myocardial enzyme levels including aspartate transaminase (AST), creatine kinase (CK-MB) and lactic dehydrogenase (LDH). It also decreased the production of inflammatory cytokines (IL-1β, IL-18, IL-6 and TNF-α) in serum of Ml/R rats. Further mechanism studies demonstrated that BCA inhibited inflammatory reaction through blocking TLR4/NF-kB/NLRP3 signaling pathway. The present study is the first evidence demonstrating that BCA attenuated Ml/R injury through suppressing TLR4/NF-kB/NLRP3 signaling pathway-mediated anti-inflammation pathway.
- RetractionOpen Access
- 1 February 2019
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 19 (4) , 2969
[Retracted] Pathogenetic mechanism of lipoid proteinosis caused by mutation of the extracellular matrix protein 1 gene
After the publication of the above article, the Editor of Molecular Medicine Reports received an accusation that this paper contained material taken from the PhD thesis of Dr Xiao Bai of the China Academy of Medical Science & Peking Union Medical College, whose thesis entitled "Study on mutations of ECM1 in lipoid proteinosis" was published online in 2015. After having enquired with the authors regarding this allegation, the first author and the corresponding author, Dr Dong Gao, admitted that she had infringed the rights of Dr Bai, and that it was not appropriate that the following figures were published in the research article: Figs. 1, 2, 4, 5, 6 and 7, which coincided with Figs. 3, 19, 27, 29, 31, and 32 in her PhD thesis, respectively. Furthermore, the above article was submitted to Molecular Medicine Reports by Dr Gao without the prior knowledge of all the other authors. Therefore, Dr Gao has agreed with the recommendation of the Editor of Molecular Medicine Reports that the above article should be retracted from the publication on account of the inappropriate use of the figures, and for submitting the article without having received the approval of all the authors. All the named authors on the paper agree to the retraction. Dr Gao regrets her actions and the inconvenience that this retraction has caused, and sincerely apologizes to Dr Bai, to the Editor, and to the readership of the Journal. [the original article was published in Molecular Medicine Reports 17: 8087‑8090, 2018; DOI: 10.3892/mmr.2018.8928].
- 1 February 2019
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 19 (4) , 2969
RetractionOpen Access[Retracted] Pathogenetic mechanism of lipoid proteinosis caused by mutation of the extracellular matrix protein 1 gene
After the publication of the above article, the Editor of Molecular Medicine Reports received an accusation that this paper contained material taken from the PhD thesis of Dr Xiao Bai of the China Academy of Medical Science & Peking Union Medical College, whose thesis entitled "Study on mutations of ECM1 in lipoid proteinosis" was published online in 2015. After having enquired with the authors regarding this allegation, the first author and the corresponding author, Dr Dong Gao, admitted that she had infringed the rights of Dr Bai, and that it was not appropriate that the following figures were published in the research article: Figs. 1, 2, 4, 5, 6 and 7, which coincided with Figs. 3, 19, 27, 29, 31, and 32 in her PhD thesis, respectively. Furthermore, the above article was submitted to Molecular Medicine Reports by Dr Gao without the prior knowledge of all the other authors. Therefore, Dr Gao has agreed with the recommendation of the Editor of Molecular Medicine Reports that the above article should be retracted from the publication on account of the inappropriate use of the figures, and for submitting the article without having received the approval of all the authors. All the named authors on the paper agree to the retraction. Dr Gao regrets her actions and the inconvenience that this retraction has caused, and sincerely apologizes to Dr Bai, to the Editor, and to the readership of the Journal. [the original article was published in Molecular Medicine Reports 17: 8087‑8090, 2018; DOI: 10.3892/mmr.2018.8928].
- Open Access
- 1 January 2017
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 8 (16) , 3183-3189
Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model
Chemo- and radio-therapy suffer from certain well-recognized drawbacks for lymphoma therapy. Passive immunotherapy with monoclonal antibody has improved outcome for patients with CD20+ B cell lymphoma, but not for T cell lymphoma. Therefore, novel treatment approaches are clearly required for T cell lymphoma. To date, the combined application targeting TLR7, 8 and 9 has established long-term antitumor immunity. We previously synthesized a purine-scaffold TLR7 agonist named GD5. Here, we report that the intratumoral administration of GD5 combined with doxorubicin (DOX), a conventional chemotherapeutic agent in T cell lymphoma. This combined treatment made mice to produce more cytokines in blood, and generate more potent cytotoxic T lymphocyte response, then result in effective eradication of both local and distant tumors in tumor-bearing mice. Our findings demonstrate the potential for enhancing the efficacy of the current standard DOX therapy through combination with TLR7 agonist GD5 to improve antitumor immune responses and provide durable remissions for T cell lymphoma.
- 1 January 2017
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 8 (16) , 3183-3189
Open AccessSynergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model
Chemo- and radio-therapy suffer from certain well-recognized drawbacks for lymphoma therapy. Passive immunotherapy with monoclonal antibody has improved outcome for patients with CD20+ B cell lymphoma, but not for T cell lymphoma. Therefore, novel treatment approaches are clearly required for T cell lymphoma. To date, the combined application targeting TLR7, 8 and 9 has established long-term antitumor immunity. We previously synthesized a purine-scaffold TLR7 agonist named GD5. Here, we report that the intratumoral administration of GD5 combined with doxorubicin (DOX), a conventional chemotherapeutic agent in T cell lymphoma. This combined treatment made mice to produce more cytokines in blood, and generate more potent cytotoxic T lymphocyte response, then result in effective eradication of both local and distant tumors in tumor-bearing mice. Our findings demonstrate the potential for enhancing the efficacy of the current standard DOX therapy through combination with TLR7 agonist GD5 to improve antitumor immune responses and provide durable remissions for T cell lymphoma.